According to the New York Times, Eli Lilly has paused its antibody treatment trials due to concerns of potential safety. This comes as Johnson & Johnson announced on Tuesday that it would be pausing its coronavirus vaccine trial in order to investigate into a patient which fell ill. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.
JEN ROGERS: Want to go to a little bit of breaking news here with Anjalee Khemlani on these-- another trial. I know this is a different kind of trial, not a vaccine trial, an antibody therapy trial here. But we talk to you often about all of the different treatments and vaccines that are coming to market and being tested, and then we keep hearing about these pauses. So you bring us up to speed on this latest headline?
ANJALEE KHEMLANI: Sure, so the latest one is Eli Lilly, which has a testing and monoclonal antibody, and they did, in fact, already apply for emergency use authorization. And I have pointed out then that it was before the trial is over and sort of before a regulatory body would be, you know, more interested in the broader data that's available. And so what this really sets up is, I've got to tell you, there's some health experts in little pockets right now smirking and smiling and feeling very vindicated, because there have been so many discussions about how, you know, how disruptive the process can be, how it's not necessarily a smooth ride to the finish line, and what we've seen in the last really 24 hours kind of really depict that.
So Eli Lilly with that monoclonal antibody, it's kind of along the same lines as Regeneron. Remember, that the treatment that the president received when he was sick in the hospital. And so we're looking at that, and it's been seen as sort of this bridge, if you will, between vaccines and treatments, because it has both properties that can, in fact, treat the virus, as well as, you know, for those individuals who are unable to receive a vaccine, they are able to receive this instead. So all eyes on that, and what it means unclear really on the details just yet. Still waiting to hear more.
Meanwhile, we also heard yesterday that Johnson-- late last night, sorry, Johnson & Johnson has paused it's vaccine trial, again, moving into the vaccine space now, and that is interesting, because we know that Johnson & Johnson sort of set itself apart from some of the other contenders with a much larger trial of 60,000 people as well as a single dose vaccine. But meanwhile, it is similar to AstraZeneca, which is, again, yet another company that had to put its vaccine trial on hold last month. Has not restarted in the US, but it did restart in the UK, and that was based off of one adverse event. We're still waiting on more details on Johnson & Johnson as well, but just interesting to note the sort of normal, and a lot of people are saying this is exactly what happens in the process.
JEN ROGERS: Right, and it's normal in an abnormal process. One other headline that stood out is that Pfizer is going to enroll kids as young as 12 into vaccine trials. Is that something that we would expect to see rolled out across other testing?
ANJALEE KHEMLANI: It's really hard to answer that with a hard yes or no. It's something that all the vaccine companies are looking at, and you kind of have to see how they're all going to play in this very big broad field of a market, because there are some that have proven to be more effective on say older adults and therefore would be likely to corner that market, and meanwhile, Pfizer is clearly targeting the younger population. So it's going to be interesting to see how that all pans out. But right now, safe to say that others are looking at, and there have been questions about not just for younger children as well, but also for pregnant women or those who are breastfeeding. So there's a lot going on in terms of the different sort of specialty segments that these vaccine companies have to look at.
JEN ROGERS: All right, Anjalee Khemlani with the very latest as we're watching shares of Eli Lilly on this news off just about 3.5%.